Pharmacokinetics and clinical efficacy of moxalactam in biliary tract infections

Moxalactam exhibited excellent in vitro activity against all pathogens commonly associated with biliary tract infections. The drug retained bactericidal activity against all of these organisms, with the possible exception of Klebsiella pneumoniae, even in the presence of bile. Pharmacokinetic studies revealed high concentrations of moxalactam in the bile after intravenous administration. Twenty-seven of 28 patients with severe, complicated biliary tract infections responded favorably to the administration of moxalactam.